U.S. markets closed

MERCK Kommanditgesellschaft auf Aktien (MRK.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
153.60+2.15 (+1.42%)
At close: 5:35PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close151.45
Open150.55
Bid153.35 x 6700
Ask153.40 x 11200
Day's Range149.65 - 153.60
52 Week Range99.30 - 157.00
Volume255,184
Avg. Volume362,917
Market Cap66.782B
Beta (5Y Monthly)0.49
PE Ratio (TTM)29.32
EPS (TTM)5.24
Earnings DateAug 05, 2021
Forward Dividend & Yield1.40 (0.91%)
Ex-Dividend DateApr 26, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • This New Product Is Central to mRNA Vaccines -- But Should You Buy the Stock?
      Motley Fool

      This New Product Is Central to mRNA Vaccines -- But Should You Buy the Stock?

      Will the timely new product position Merck KGaA as an upstream supplier for the entire mRNA medicine world and allow it to reap the benefits, or is it unlikely to reward shareholders? To start, let's quickly review the scientific concepts at hand so that it's clear why Merck KGaA's new product is worth knowing about. As you may know, lipid molecules don't dissolve in water.

    • MERCK KGAA (MKKGY) Q1 2021 Earnings Call Transcript
      Motley Fool

      MERCK KGAA (MKKGY) Q1 2021 Earnings Call Transcript

      MKKGY earnings call for the period ending March 31, 2021.

    • Reuters

      UPDATE 1-Lab supplier Merck KGaA says U.S. Defense Production Act poses challenge

      Merck KGaA on Wednesday said that U.S. regulations that give priority to U.S. government contracts to purchase COVID-19 vaccines are a challenge as it seeks to meet soaring demand for its lab equipment and supplies across the globe. She said U.S. law required that a preference be given to so-called rated state orders for COVID-19 programmes over any other orders. "For us, all our customers and all the other COVID-19 programmes are very crucial and we are making capacity expansion a top priority of our agenda," she said, pointing to investment projects both in the United States and Europe.